• Publications
    Expected Returns Articles
  • Research
    Companies Funds Top 40 My Studies
  • Stock Screen
    New Stock Screen Manage Screens
  • Dashboards
    My Dashboards New Dashboard
  • Forum
  • Events
  • Search
  • Contact Us
  • Sign In

Biogen (BIIB)

Company Ticker Sector | Industry Quality PAR
Biogen BIIB Healthcare | Drug Manufacturers - General 38 8.1%
Current Price (10/31 4:00PM EDT) $154.27
Projected Return on Value (PROVE) 10.1%
Expected Income Statement
Current Sales 9,818.0
Sales Growth Forecast 0.8%
Net Profit Margin 19.0%
Projected Shares Outstanding 149.67
EPS - Five year Forecast $12.95
Average P/E Ratio 17.6
Projected Average Price $228.00
Price Appreciation (Annualized) 8.1%
Annual Dividend Yield 0.0%
Projected Annual Return 8.1%
Quality
Financial Strength 40 10.1
EPS Stability 56 14.1
Industry Sales Growth Rate 4.0% 2.4
Industry Net Profit Margin 19.3% 12.3
Calculated Quality Rating 38.9
Fundamental Data Updated: 08/29/2025
MIPAR 9.3%  
Sweet Spot 14.3% - 19.3%  
Top In Drug Manufacturers - General
Ticker Quality PAR
AMGN 87 12.5%
MRK 89 10.6%
AZN 91 9.3%
ABBV 95 7.5%
RHHBY 63 14.8%
Top In Healthcare
Ticker Quality PAR
UFPT 97 16.3%
LNTH 84 18.6%
HSIC 90 17.2%
ALGN 83 20.1%
NBIX 83 17.9%

© 2006 - 2025 Manifest Investing. All rights reserved.
About | Terms of Service | Disclaimer | Privacy Policy

Legend
Quality Legend:
Blue Excellent with quality greater than 80.
Green Good with quality between 60 and 80.
Neutral Average or below average with quality between 20 and 60.
Red Poor with quality less than 20.
Companies with less than 10 years of history are penalized by 5 points per year.
PAR Legend:
Green PAR is within the target range of MIPAR +5-10%, currently 5.1%-10.1%
Yellow PAR is above the target range of MIPAR +10%, currently 10.1%
PAR Projected Annual Return
MIPAR The Manifest Investing Median PAR of all stocks in the database.
Company Name Legend:
* Not covered by Value Line Standard Edition.
b Uses price-to-book value for valuation purposes.
P/CF Uses price-to-cash flow for valuation.